Cerebral vasospasm.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D001792:Blood Platelets / Q000378:metabolism; D002245:Carbon Dioxide / Q000627:therapeutic use; D002395:Catecholamines / Q000494:pharmacology; D002746:Chlorpromazine / Q000627:therapeutic use; D004195:Disease Models, Animal; D004221:Disulfiram / Q000627:therapeutic use; D006801:Humans; D002546:Ischemic Attack, Transient / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D009125:Muscle Relaxants, Central / Q000627:therapeutic use; D009599:Nitroprusside / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors; D011453:Prostaglandins / Q000494:pharmacology; D012701:Serotonin / Q000494:pharmacology; D012702:Serotonin Antagonists; D014439:Tyramine / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D002395:Catecholamines; D009125:Muscle Relaxants, Central; D010726:Phosphodiesterase Inhibitors; D011453:Prostaglandins; D012702:Serotonin Antagonists; D000804:Angiotensin II; D002245:Carbon Dioxide; D009599:Nitroprusside; D012701:Serotonin; D004221:Disulfiram; D002746:Chlorpromazine; D014439:Tyramine